Lung Cancer RNA Panel (ALK, RET, ROS1 & MET Mutations)

Available Now

Product Name/Description
No. of Reactions*
Product Code
Lung Cancer RNA Panel (ROS1, RET, ALK & MET Mutations)
48
LUNG-RT48

* Includes all controls

Fusion Genes in Lung Cancer

Non–small-cell lung cancer (NSCLC) is frequently associated with aberrant tyrosine kinase activity that abnormally activates downstream signaling pathways. Aberrant tyrosine kinase activity has been linked to chromosomal translocations involving ALK, ROS1 and RET which are found in 3-7%, ~2%, and ~1% of patients with NSCLC, respectively. The presence of ALK and ROS1 fusion genes predicts response to several recently approved tyrosine kinase inhibitors (TKIs) (crizotinib, ceritinib and alectinib). Lung cancer patients harboring RET fusion genes may be candidates for RET inhibitors (vandetanib and cabozantinib) which are approved for thyroid cancer treatment.

MET exon 14 skipping mutations are also frequently detected in lung adenocarcinoma and occur in 3-4% of patients. Patients that are positive for MET exon 14 skipping mutations show increased sensitivity to MET inhibitors, including crizotinib and cabozantinib.

Kit Features

The Lung Cancer RNA Panel provides reagents for detecting ALK, ROS1, and RET fusion genes as well as MET exon 14 skipping mutations in human lung RNA.

The one-step assay combines first-strand cDNA synthesis (reverse transcription) and subsequent amplification of mutant and reference genes, minimizing hands-on time and reducing the risk of introducing contaminants during the workflow. The kit detects a total of 47 variants (see tables below) in 8 reactions.

This kit is compatible with various sample types and can be used to detect mutations in RNA isolated from fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples.

ALK Fusion Gene Variant Chromosomal Translocation
EML4-ALK E13;A20
E20;A20
E20;ins18A20
E6;A20
E6ins33;A20
E6;ins18A20
E14ins11;del49A20
E2;A20
E2;ins117A20
E13;ins69A20
E14;del14A20
E14;del36A20
E17;ins30A20
E17ins61;ins34A20
E17del58ins39;A20
E17ins65;A20
E17;ins68A20
E15del60;del71A20
E18;A20
E3;ins53A20
E6;A19
ROS1 Fusion Gene Variant Chromosomal Translocation
SLC34A2-ROS1 S4;R32
S13del;R32
S4;R34
S13del;R34
CD74-ROS1 C6;R32
C7;R32
C6;R34
SDC4-ROS1 S2;R32
S4;R32
S4;R34
EZR-ROS1 E10;R34
LRIG3-ROS1 L16;R35
TPM3-ROS1 T8;R35
GOPC-ROS1 G7;R35
G4;R36
RET Fusion Gene Variant Chromosomal Translocation
KIF5B-RET K15;R12
K16;R12
K22;R12
K23;R12
K24;R8
K24;R11
K15;R11
CCDC6-RET C1;R12
NCOA4-RET N6;R12
TRIM33-RET T14;R12
Gene Mutation
MET Exon 14 skipping

 

Equipment & Materials

The Lung Cancer RNA Panel requires a real-time PCR instrument capable of detecting FAM, VIC and CY5 fluorescent probes. This kit includes primer/probe mix for detection of all variants mentioned above, one-step enzyme mix for cDNA synthesis and PCR detection, as well as validated controls. Columns and reagents for RNA isolation are not included.

 

Intended Use

USA:

EntroGen’s Lung Fusion Gene Panel is available for research use only (RUO). Not for use in diagnostic procedures.

Europe: 

EntroGen’s Lung Fusion Gene Panel is available for research (RUO) and diagnostic (CE-IVD) purposes.